Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ISC 2018: COMPASS Supports First-Line Aspiration With Penumbra's System

Executive Summary

Results of the COMPASS trial showed that Penumbra's aspiration system is non-inferior to stent-retrievers as a first-line therapy to treat acute ischemic stroke. COMPASS was one of several important device trials featured at the presented at the International Stroke Conference held in Los Angeles.

You may also be interested in...



Device Debut: Medtronic Pulls Riptide Into Growing Stroke Offering

Riptide complements Medtronic's Solitaire stent retriever revascularization device for the treatment of acute ischemic stroke. The company began rolling out Riptide at this year's International Stroke Conference, which also featured the presentation of important clinical data supporting aspiration as a first-line therapy for stroke.

NANS 2020: Medtronic’s DTM Spinal Cord Stimulation Relieves Back Pain In Trial

Three-month results from a 94-patient randomized trial of Medtronic’s Intellis spinal cord stimulation system showed superior back-pain relief with the differential target multiplexed waveform compared to conventional spinal cord stimulation.

2019 Device Approvals Review: Original PMAs Up, De Novos Down

The US FDA approved fewer novel devices in 2019 than in 2018, despite a slight increase in original PMA approvals. De novo clearances were down significantly after four straight years of increases, while panel-track PMA supplements and 510(k) clearances also declined from the 2018 totals.

Topics

Related Companies

UsernamePublicRestriction

Register

MT122125

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel